These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 30549279)

  • 1. Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection.
    Feld JJ; Terrault NA; Lin HS; Belle SH; Chung RT; Tsai N; Khalili M; Perrillo R; Cooper SL; Ghany MG; Janssen HLA; Lok AS;
    Hepatology; 2019 Jun; 69(6):2338-2348. PubMed ID: 30549279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Entecavir/Peginterferon Alfa-2a in Children With Hepatitis B e Antigen-Positive Immune Tolerant Chronic Hepatitis B Virus Infection.
    Rosenthal P; Ling SC; Belle SH; Murray KF; Rodriguez-Baez N; Schwarzenberg SJ; Teckman J; Lin HS; Schwarz KB;
    Hepatology; 2019 Jun; 69(6):2326-2337. PubMed ID: 30318613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation.
    Chen CC; Wang PC; Chang HW; Chen CF
    J Viral Hepat; 2012 Mar; 19(3):161-72. PubMed ID: 22329370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
    Hsu CW; Su WW; Lee CM; Peng CY; Chuang WL; Kao JH; Chu HC; Huang YH; Chien RN; Liaw YF
    J Formos Med Assoc; 2018 Jul; 117(7):588-597. PubMed ID: 29456079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study.
    Chan HLY; Chan FWS; Hui AJ; Li MKK; Chan KH; Wong GLH; Loo CK; Chim AML; Tse CH; Wong VWS
    J Viral Hepat; 2019 Jan; 26(1):126-135. PubMed ID: 30187604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
    Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
    J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
    Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.
    Xie Q; Zhou H; Bai X; Wu S; Chen JJ; Sheng J; Xie Y; Chen C; Chan HL; Zhao M
    Clin Infect Dis; 2014 Dec; 59(12):1714-23. PubMed ID: 25190434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
    Chen XF; Chen XP; Ma XJ; Chen WL; Luo XD; Liao JY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):502-5. PubMed ID: 24074707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
    Gish RG; Lau DT; Schmid P; Perrillo R
    Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Twenty-four weeks therapy with peginterferon alfa-2a could be similar to 48 weeks therapy in patients with HBeAg positive chronic hepatitis B and good predictors of response: results of a pilot study].
    Solari J; Galdame O; Rezzonico L; Frider B; Villamil A; Casciato P; Reig M; Bandi JC; Alessio A; Gadano A
    Acta Gastroenterol Latinoam; 2009 Dec; 39(4):254-60. PubMed ID: 20178254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
    Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N;
    N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.
    Chen CH; Lee CM; Hung CH; Wang JH; Hu TH; Changchien CS; Lu SN
    J Gastroenterol Hepatol; 2011 Mar; 26(3):461-8. PubMed ID: 21332543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.